These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37672511)

  • 1. Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
    Liu S; Li H; Xue Y; Yang L
    PLoS One; 2023; 18(9):e0290888. PubMed ID: 37672511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
    Huan L; Yu F; Cao D; Zhou H; Qin M; Cao Y
    PLoS One; 2024; 19(3):e0295983. PubMed ID: 38451955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
    Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
    Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials.
    Aliseda D; Martí-Cruchaga P; Zozaya G; Blanco N; Ponz M; Chopitea A; Rodríguez J; Castañón E; Pardo F; Rotellar F
    BJS Open; 2024 Sep; 8(5):. PubMed ID: 39329454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
    Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B;
    BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.
    Ye M; Zhang Q; Chen Y; Fu Q; Li X; Bai X; Liang T
    HPB (Oxford); 2020 Jun; 22(6):821-832. PubMed ID: 32001139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
    Unno M; Hata T; Motoi F
    Surg Today; 2019 Apr; 49(4):295-299. PubMed ID: 30877550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
    Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
    J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
    Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
    Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
    Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
    Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer.
    Cucchetti A; Crippa S; Dajti E; Binda C; Fabbri C; Falconi M; Ercolani G
    Eur J Surg Oncol; 2022 Sep; 48(9):1994-2001. PubMed ID: 35491363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
    Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X
    World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.
    Ghanem I; Lora D; Herradón N; de Velasco G; Carretero-González A; Jiménez-Varas MÁ; Vázquez de Parga P; Feliu J
    ESMO Open; 2022 Jun; 7(3):100485. PubMed ID: 35580504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials.
    Uson Junior PLS; Dias E Silva D; de Castro NM; da Silva Victor E; Rother ET; Araújo SEA; Borad MJ; Moura F
    ESMO Open; 2023 Feb; 8(1):100771. PubMed ID: 36638709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Cloyd JM; Heh V; Pawlik TM; Ejaz A; Dillhoff M; Tsung A; Williams T; Abushahin L; Bridges JFP; Santry H
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32326559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.